<DOC>
	<DOCNO>NCT00889694</DOCNO>
	<brief_summary>This study 12-week , randomize , placebo positive drug control clinical trial investigate whether tripterygium capsule effective safe treat patient ankylose spondylitis . The investigator expect tripterygium capsule effective placebo adverse effect .</brief_summary>
	<brief_title>Clinical Study Tripterygium Capsule Treat Early Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>1 . Fulfill ESSG criterion SpA fulfill criterion subtype include ankylose spondylitis , psoriatic arthritis , reactive arthritis inflammatory bowel disease associate arthritis . 2 . Disease active status define BASDAI &gt; =40mm . 3 . DMARDs administration must suspend least 4 week screen . NSAIDs dose must stable least 4 week screen . 1 . Intraarticular injection glucocorticoid within 3 month . 2 . Previous history heart failure , multiple sclerosis , chronic obstructive pulmonary disease , recurrent infection , lymphoma tumor . 3 . Accompanied fibromyalgia syndrome rheumatic disease . 4 . Female pregnancy breastfeed . 5 . Poor compliance mental disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>